Skip to main content
. Author manuscript; available in PMC: 2022 Jul 20.
Published in final edited form as: Brain Behav Immun. 2020 Jan 30;87:473–488. doi: 10.1016/j.bbi.2020.01.018

Figure 4. Serum markers and Principal Components Analysis.

Figure 4

(A)-(E) - Concentrations of serum (A) alpha-synuclein, (B) caspase-1, (C) endotoxin, (D) soluble CD14 and (E) soluble TREM2 in Parkinson’s disease patients and controls and within Parkinson’s dementia risk groups. (Patients=red; Controls=yellow). **significance withstood Bonferroni correction for multiple testing within the relevant category.

(F)-(H) - Summary of Principal Components Analysis (PCA) component score comparisons between all Parkinson’s patients and paired controls and within risk groups. (Patients=red; Controls=yellow).

Component 1 - (+)serum alpha-synuclein, (+)caspase-1 and (-)TLR2+ monocytes; Component 2 - (+)serum endotoxin, (+)monocyte TREM2 and (-)serum alpha-synuclein; Component 3 - (+)classical monocyte percentage and (-)serum alpha-synuclein